Filing Details

Accession Number:
0001735276-24-000083
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-14 16:12:07
Reporting Period:
2024-08-12
Accepted Time:
2024-08-14 16:12:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1886431 Joseph Kevin Fitzgerald 675 West Kendall Street
Henri A. Termeer Square
Cambridge MA 02142
Cso & Evp, Head Of Research No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-08-12 6,667 $97.72 20,848 No 4 M Direct
Common Stock Acquisiton 2024-08-12 14,058 $85.00 34,906 No 4 M Direct
Common Stock Disposition 2024-08-12 1,421 $268.66 33,485 No 4 S Direct
Common Stock Disposition 2024-08-12 9,662 $270.17 23,823 No 4 S Direct
Common Stock Disposition 2024-08-12 5,736 $271.32 18,087 No 4 S Direct
Common Stock Disposition 2024-08-12 3,913 $272.43 14,174 No 4 S Direct
Common Stock Disposition 2024-08-12 1,158 $273.73 13,016 No 4 S Direct
Common Stock Disposition 2024-08-12 135 $274.65 12,881 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2024-08-12 14,058 $0.00 14,058 $85.00
Common Stock Stock Option (right to buy) Disposition 2024-08-12 6,667 $0.00 6,667 $97.72
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,192 2029-02-28 No 4 M Direct
0 2025-12-07 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 537 Indirect by Managed Account
Footnotes
  1. All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.
  2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $268.53 to $269.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $269.90 to $270.87. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $271.02 to $271.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $272.23 to $272.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $273.32 to $274.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  7. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
  8. This stock option was fully vested and exercisable as of February 28, 2023.
  9. This stock option was fully vested and exercisable as of December 7, 2015.